Company Monitoring Page for JNJ

latest headlines for company on cafepharma

ASCO-GU – prostate cancer PARPS move to the front line
EP Vantage
Sun, 02/20/22 - 11:44 am
Tags:
prostate cancer, ASCO-GU, PARP inhibitors, Lynparza, Zejula, Rubraca, Talzenna, biomarkers, AstraZeneca, Merck, GSK, JNJ, Clovis Oncology
Remix Therapeutics signs Janssen licensing deal that could top $1B
Fierce Biotech
Thu, 02/17/22 - 10:53 am
Tags:
Remix Therapeutics, RNA, Janssen, JNJ, small molecule drugs
As Johnson & Johnson fights for bankruptcy ploy in talc litigation, Congress is weighing in
Fierce Pharma
Wed, 02/16/22 - 11:07 pm
Tags:
JNJ, US Congress, legal, bankruptcy
AstraZeneca/Merck come out of ASCO GU with a big win over J&J in battle over prostate cancer franchises
Endpoints
Tue, 02/15/22 - 11:31 pm
Tags:
AstraZeneca, Merck, JNJ, ASCO, prostate cancer, Lynparza
AC Immune's Janssen-partnered Alzheimer's vaccine spurs tau-attacking antibodies in early-stage trial
Fierce Biotech
Tue, 02/15/22 - 10:32 am
Tags:
AC Immune, Janssen, JNJ, vaccines, Alzheimer's disease, clinical trials
J&J's Blue Jacket Fashion Show returns live to boost prostate cancer awareness
Fierce Pharma
Tue, 02/15/22 - 10:29 am
Tags:
pharma marketing, JNJ, Janssen, oncology, prostate cancer
The biggest launches of 2022: a reboot
EP Vantage
Mon, 02/14/22 - 10:48 am
Tags:
drug launches, Eli Lilly, tirzepatide, Alnylam, vutrisiran, Roche, Vabysmo, JNJ, Carvykti, Mirati Therapeutics, adagrasib, Bristol Myers Squibb, mavacamten, deucravacitinib
Robots cushion omicron's blow to Q4 orthopaedic device sales
Medtech Dive
Wed, 02/9/22 - 10:04 am
Tags:
Medtech, devices, earnings, Zimmer Biomet, Stryker, JNJ, COVID-19, robotic surgery
J&J pauses COVID-19 vaccine production at Dutch plant in temporary pivot to RSV shot: NYT
Fierce Pharma
Tue, 02/8/22 - 11:57 pm
Tags:
JNJ, vaccines, COVID-19, RSV, drug manufacturing
J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets
Fierce Biotech
Thu, 02/3/22 - 11:18 am
Tags:
JNJ, Janssen, Mersana, antibody-drug conjugate, biobucks
J&J Is Hungry for Medical Device M&A
Medical Devices and Diagnostics Industry
Wed, 01/26/22 - 11:05 am
Tags:
JNJ, devices, Medtech, M&A
Go or no go? PDUFA resolutions eyed for J&J and Amryt
EP Vantage
Wed, 01/26/22 - 10:40 am
Tags:
FDA, JNJ, Legend Biotech, ciltacabtagene autoleucel, Amryt, Oleogel-S10
J&J 'constantly looking' at biotech M&A, but focused on small, mid-sized deals
BioPharma Dive
Tue, 01/25/22 - 11:45 pm
Tags:
JNJ, M&A, devices
J&J expects more than $3 billion in Covid vaccine sales this year in mixed quarterly report
CNBC
Tue, 01/25/22 - 11:41 pm
Tags:
JNJ, earnings, vaccines, COVID-19
Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach
Endpoints
Tue, 01/25/22 - 10:58 am
Tags:
intranasal sprays, COVID-19, JNJ, Leyden
COVID vaccines help Pfizer, Moderna reign supreme reputation-wise, but they're a double-edged sword for J&J and AZ
Fierce Pharma
Thu, 01/20/22 - 11:23 pm
Tags:
Pfizer, Moderna Therapeutics, JNJ, AstraZeneca, COVID-19, vaccines, reputation
Will Johnson & Johnson Be a Better Buy After Spinning Off Its Consumer Business?
Motley Fool
Thu, 01/20/22 - 11:02 am
Tags:
JNJ, spinoffs, consumer health
J&J’s investment arm joins $150M investment in digital health firm Verana
MedCity News
Mon, 01/17/22 - 10:15 am
Tags:
JNJ, Verana Health, digital health, VeraQ
FDA adds rare bleeding risk to J&J shot side effects
Beckers Hospital Review
Thu, 01/13/22 - 07:26 am
Tags:
FDA, vaccines, JNJ, chronic immune thrombocytopenia, COVID-19
JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch
Fierce Pharma
Wed, 01/12/22 - 11:22 pm
Tags:
JPMHC 2022, Bausch Health, Amgen, Eli Lilly, Perrigo, JNJ, Legend Biotech

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.